Skip to main content
Werewolf Therapeutics, Inc. logo

Werewolf Therapeutics, Inc. — Investor Relations & Filings

Ticker · HOWL ISIN · US95075A1079 US Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2025-05-08 Capital/Financing Update
Country US United States of America
Listing US HOWL

About Werewolf Therapeutics, Inc.

https://werewolftx.com/

Werewolf Therapeutics, Inc. is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company utilizes its proprietary PREDATOR® protein engineering platform to create a novel class of conditionally activated proinflammatory immune modulators, known as INDUKINE™ and INDUCER™ molecules. These therapies are designed to be delivered systemically in an inactive state and become selectively activated within the tumor microenvironment. This approach aims to generate a potent, localized anti-tumor immune response while minimizing the systemic side effects associated with conventional immunotherapies. The company's pipeline includes clinical-stage candidates such as WTX-124 and WTX-330.

Recent filings

Filing Released Lang Actions
S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC by Werewolf Therapeutics, Inc. It is a registration statement under the Securities Act of 1933 for the offering of securities including debt securities, common stock, preferred stock, depositary shares, subscription rights, warrants, and units. The document includes a base prospectus and a sales agreement prospectus. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not just an announcement of a report, so it is not RPA or RNS. Confidence is high due to clear identification of the form and purpose.
2025-05-08 English
S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used for registering securities to be offered to employees under employee benefit plans. It includes legal and indemnification information, references to other filings like Form 10-K and 10-Q, but does not contain financial statements or management discussion. It is a regulatory filing related to securities registration, not an annual report, earnings release, or other financial report. Therefore, it fits best under Regulatory Filings (RNS). The document length is substantial and contains detailed legal and registration information, confirming it is not a brief announcement or proxy material.
2025-05-08 English
10-Q
Interim / Quarterly Report Q1 2025
2025-05-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC by Werewolf Therapeutics, Inc. dated May 8, 2025. It includes a press release announcing financial results for the quarter ended March 31, 2025, and an investor presentation. The document explicitly states that the press release is furnished as Exhibit 99.1 and the investor presentation as Exhibit 99.2. The text clarifies that the information is being "furnished" and not "filed" for certain regulatory purposes, indicating this is a current report rather than a full financial report. The document length is 8023 characters, which is relatively short and consistent with a current report rather than a full quarterly or annual report. The key content is the announcement of quarterly financial results and an investor presentation, typical of a Current Report (Form 8-K) that includes an Earnings Release and Investor Presentation. Given the presence of a press release announcing quarterly financial results, the classification aligns best with Earnings Release (ER). The investor presentation is also included but the primary financial disclosure is the earnings announcement. Therefore, the filing type is Earnings Release (ER).
2025-05-08 English
4
Director's Dealing
2025-05-02 English
Director's Dealing 2025
Director's Dealing
2025-04-30 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.